No way.If anything Trials will be faster with quicker data releases as well. Covid is going to revamp the FDA for the better. The FDA has been a bottleneck for eons,now that has to change.
Covid could obviously skew the data for a survival endpoint. Although it might be fairly easy to determine the cause of death. I wonder if the virus could in some cases actually ramp up the immune response.
Yes ADXS has gone from pre split $450 a share to $.50 a share and needing a cash infusion desperately. This one has been dead a long time but no one turned the lights out. What we do need is another $20 million dollar trial with 8 or 9 patients. BUY BYE BYE